Antibodies against transforming growth factor-beta 1 suppress intimal hyperplasia in a rat model.
AUTOR(ES)
Wolf, Y G
RESUMO
Intimal hyperplasia is induced by therapeutic vascular interventions and often results in clinically important narrowing of the vascular lumen. Examination of the role of TGF-beta 1 in a rat carotid artery injury model confirmed the presence of a previously reported increase in TGF-beta 1 mRNA in the media of injured arteries. Administration of neutralizing anti- TGF-beta 1 antibodies significantly (P < 0.05) reduced the size of the intimal lesions that developed after carotid balloon injury. A control antibody had no effect. The intimal/medial area ratio was also reduced in the anti-TGF-beta 1 group relative to controls (P < 0.01). Immunohistochemical staining showed that two TGF-beta 1-induced extracellular matrix components, EDA + fibronectin and versican, were greatly increased in the untreated neointimal lesions, but were almost completely absent from the lesions of the anti-TGF-beta 1-treated animals. We conclude that TGF-beta 1 is causally involved in the development of intimal hyperplasia, and that anti-TGF-beta 1 agents may be useful in achieving at least partial control of this condition.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=294068Documentos Relacionados
- Dominant negative mutants of transforming growth factor-beta 1 inhibit the secretion of different transforming growth factor-beta isoforms.
- Hypertrophic stimuli induce transforming growth factor-beta 1 expression in rat ventricular myocytes.
- Transforming growth factor-beta complexes with thrombospondin.
- Nucleotide sequence of chicken transforming growth factor-beta 1 (TGF-beta 1).
- Stimulation of rat endothelial cell transforming growth factor-beta production by bleomycin.